• Allarity Therapeutics received a USPTO Notice of Allowance for a patent application covering its stenoparib DRP companion diagnostic.
• Patent is expected to be formally granted within three months, subject to standard administrative procedures.
• Allarity expects patent to provide US exclusivity at least into 2039 for stenoparib when used with stenoparib DRP test.
• Allowed claims cover methods to predict clinical benefit from tumor gene-expression profiles to select patients for stenoparib.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604270800PRIMZONEFULLFEED1001178130) on April 27, 2026, and is solely responsible for the information contained therein.